000 04345nam a22004575i 4500
999 _c120517
_d120517
_x1
001 120517
003 ES-MaUEC
005 20230102114046.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200403s2020 si a o |||| 0|eng d
020 _a9789811525179
024 7 _a10.1007/978-981-15-2517-9
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC685.C6
_b2020 EB
245 0 0 _aCoronary Artery Disease: Therapeutics and Drug Discovery /
_cedited by Miao Wang.
250 _aFirst edition
264 1 _aSingapore
_bSpringer International Publishing
_c2020
300 _a1 recurso en línea (IX, 339 páginas)
_b7 ilustraciones, 4 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aAdvances in Experimental Medicine and Biology
_x0065-2598
_v1177
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aCoronary Artery Disease: From Mechanism to Clinical Practice -- Evidence in guidelines for treatment of coronary artery disease -- Revascularization For Coronary Artery Disease: Principle And Challenges -- Antithrombotic drugs: pharmacology and perspectives -- Lipid modifying drugs: pharmacology and perspectives -- Anti-hypertensive drugs: pharmacology and perspectives -- Pharmaceutical treatment for Heart failure -- Drug discovery for coronary artery disease.
520 3 _aThis book provides an overview of the etiology of coronary artery disease and focuses on the main therapies and drug interventions currently available. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease. The book is divided into eight chapters, the first of which describes the classical mechanism of coronary artery disease and its clinical presentations. Chapter 2 lists the principles of and related evidence on the prevention and treatment of coronary artery disease. This includes diet and lifestyle management, and guidelines for the treatment of acute coronary syndrome and stable coronary artery disease. In turn, Chapter 3 describes revascularization treatments, covering percutaneous coronary interventions, coronary artery bypass grafts and thrombolysis. This chapter also addresses the main therapeutic challenges. The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure constitutes the major health burden in the late stage of coronary artery disease; accordingly, current heart failure therapeutics and related drug pharmacology are described in Chapter 7. In closing, Chapter 8 provides a summary of on-going clinical trials for coronary artery disease drug development and discusses a number of promising areas in which intensive research into new therapeutics is being pursued. Given its scope, the book will be of interest to clinicians, medical students and research scientists, as well as to pharmaceutical professionals who are seeking new therapies and drugs for coronary artery disease and related disorders.
988 _aSpringer_Biomedlife_23062020
650 7 _aCardiopatía coronaria
_xTratamiento
_2embne
_9674641
650 7 _aCardiopatía isquémica
_xTratamiento
_2embne
_9674642
650 7 _aCorazón
_xEnfermedades
_2embne
_9169667
700 1 _aWang, Miao
_eeditor
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_0http://id.loc.gov/authorities/names/n80136573
_1http://viaf.org/viaf/95342243
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_1http://viaf.org/viaf/148105729
776 0 8 _iPrinted edition:
_z9789811525162
776 0 8 _iPrinted edition:
_z9789811525186
776 0 8 _iPrinted edition:
_z9789811525193
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v1177
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-15-2517-9
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b07/2020
_dz
_eo
_zSI